BerGenBio to Present at Upcoming Scientific Conferences
– Data on AXL as a therapeutic target in lung cancers to be highlighted at AACR – – Ph1a/2b 1L STK11m NSCLC trial design to be outlined at ELCC – BERGEN, Norway, March 28,2023 – BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical needs, today announced that the Company will be presenting three posters at two upcoming scientific conferences: ESMO’s European Lung Cancer Congress (ELCC) 2023 and the American Association for Cancer Research (AACR) Annual Meeting 2023. European Lung Cancer